The Globe and Mail reports in its Tuesday edition that CIBC analyst Scott Fletcher has cut Well Health Technologies to "neutral" from "outperformer." The Globe's David Leeder writes that Mr. Fletcher gave his share target a 75-cent trim to $4.75. Analysts on average target the shares at $8.08. Mr. Fletcher says in a note: "[Well Health Technologies] faced margin headwinds across its business in 2023 and we expect margins to remain pressured into 2024, slowing EBITDA growth. We are also adjusting our valuation to better account for shareholders' portion of [Well Health's] EBITDA, leading to a reduction in our price target from $5.50 to $4.75. We prefer a wait-and-see approach as [Well Health] works to implement cost savings initiatives and integrates recent acquisitions. In addition to the [Well Health] downgrade and price target change, we are rolling our financial models forward to 2025 and updating our price target calculations." The Globe reported on Jan. 26, 2022, that Mr. Fletcher said Well Health was facing a "sector-wide contraction." It was then worth $4.23. The Globe reported on Nov. 12, 2022, and Nov. 16, 2023, that Desjardins had reiterated its "hold" call for Well Health when it was worth $3.12 and $3.79.